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          INTRODUCTION 
 
 
Rett Syndrome 
 
Historical overview 
Rett syndrome (RTT) was first identified by Dr. Andreas Rett in 1966 after he 
observed 22 patients with similar unique symptoms (Rett 1966).  Further studies 
by Dr. Hagberg allowed Rett syndrome to be considered as a 
neurodevelopmental disorder (Hagberg et al., 1983). It is considered to be the 
second most common cause of intellectual disability in females, after Down’s 
syndrome (Hagberg 1995), with a frequency of 1:10,000 live female births. 
Though it is predominantly found in females, few cases of RTT have also been 
found in males. The disorder is clinically diagnosed based on the internationally 
accepted diagnostic criteria that were developed and adapted over the years as a 
useful tool for clinicians, involved in the diagnostic work-up, and for researchers, 
dealing with RTT (Hagberg et al., 2002; Neul et al., 2010). 
The MECP2 gene was discovered by Amir et al., (Amir et al., 1999) as the main 
genetic cause of RTT; in fact, we now recognize that MECP2 is responsible for 
>95% cases of classical RTT (Amir et al., 1999; Neul et al., 2008; Zoghbi 2005). 
On the contrary, some of the variant forms of RTT are caused by genes other 
than MECP2. Indeed, we recognize several variant forms of RTT, depending on 
the phenotype and the involved gene. The congenital variant is often caused by 
mutations in FOXG1 whereas the infantile seizure onset variant (Hanefeld 
variant) is mainly associated with CDKL5 mutations. 
 
Clinical Features and Diagnosis 
RTT syndrome has been broadly classified into two types: classical (typical) 
RTT and variant (atypical) RTT. Classic RTT patients appear to develop 
normally from 6-18 months of age. During this developmental period they 
appear to develop normal motor functions and social communication skills. The 
head-circumference of a RTT girl is normal at birth; however, its growth 
decelerates at 2-3 months of age (Schultz et al., 1993). The disorder is 
characterized by early neurological regression that severely affects motor, 
cognitive and communication skills, often leading to microcephaly, loss of 
acquired skills, absence of speech, emergence of autistic features, loss of 
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purposeful hand skills, replaced by stereotyped hand movements, other motor 
abnormalities including abnormal muscle tone, ataxia and apraxia, and often a 
seizure disorder. Many girls with RTT have autonomic perturbations, including 
irregular breathing. This includes hypoventilation or hyperventilation while 
awake, breath holding, aerophagia, forced expulsion of air and saliva, and apnea.  
 
 The RTT Cascade of Clinical Symptoms in a Staging System 
To segregate the non-specific developmental profile in early stages of life from a 
more specific profile of the disorder in the later stages, clinicians developed a 
staging system, where they delineated loss of acquired skills and communicative 
and motor dysfunctions (Engerstrom 1990). The four clinical stages of RTT are 
described as follows: 
The Early-Onset Stagnation Period (Stage I) 
This occurs between 6 months and 1.5 years of age. A sudden change in the 
interactive behavior of the girl may appear. Others may be irritable and restless 
and parents may relate frequent crying and teething. At this moment postural 
development is under progress but delayed (Dan and Cheron 2008). The child 
may learn to sit upright but not to crawl or to stand up and bottom shuffling is 
very common. Babbling of new words appears but remains poor. In short, the 
overall developmental pattern looks grossly normal at this stage. 
 
The Rapid Developmental Regression Period (Stage II) 
This stage appears between 1 and 4 years of age and is characterized by rapid 
and specific regression of acquired abilities. This may happen either suddenly, 
sometimes with pseudo-toxic symptoms (high pitched crying, fever and apathy 
suggesting meningoencephalitis), or with a gradual decline in the ability to 
communicate and in motor response. Though eye contact is still present, the 
child shows lack of interest in people and surrounding environment. Previously 
acquired words and motor skills are lost, and mental deficiency is now evident. 
Crying at night, recurrent infections or bouts of unexplained fever are common in 
this stage and often accepted as an explanation for the developmental delay. 
Febrile seizures may be present and questions about epileptic paroxysms may 
arise. A decline in head growth is also observed in most cases.  
 
The Pseudo-Stationary Stage (Stage III) 
This stage starts when the regression stage is over. If walking was previously 
acquired, the child may still be able to do so, and if not, they may still learn it. 
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But the loss of purposeful hand use is obvious. The typical hand stereotypies 
become prominent at this stage and constitute the hallmark of the disorder,  
 
showing hand wringing, hand washing and clapping as soon as the child is 
awake. The visual contact behavior returns and the child is more alert. Breathing 
abnormalities that were present in stage II may become more prominent in this 
stage. Many have overt clinical epilepsy requiring treatment, but many also 
become seizure free after some time. The feet and lower limbs are cold, with or 
without color change, and with or without atrophic changes. Motor regression 
slowly progresses in this stage whereas the ability to communicate still persists, 
mainly with the eyes. Though this stage may last for decades, the girls and 
women are able to learn about new things, situations and persons. 
 
Late Motor Deterioration (Stage IVA) 
This stage begins when the individual is unable to walk and becomes completely 
dependent on the wheel chair. Some individuals with severe RTT syndrome pass 
directly from stage II to Stage IVB, which is characterized by severe 
neurological impairment with pronounced muscle wasting and distortion of distal 
limbs. The feet are cold and hand stereotypies become less intense with age. In 
these quadriplegic females the lack of motor activity finally leads to a state of 
frozen rigidity. However, significant eye-contact and eye pointing behavior is 
still present even in the most severe situations. 
 
Diagnostic criteria 
In spite of molecular genetics, diagnosis of Rett syndrome remains mainly 
clinical. For this purpose a set of clinical observations are made to classify the 
disorder (Table 1). Variant RTT can be identified with slightly different set of 
clinical symptoms (Table 2): at least 2 out of 4 main criteria (a clinical profile 
characterized by a regression stage followed by a recovery of interaction while 
neuromotor regression continues, reduced hand skills, hand stereotypies, reduced  
babble speech, reduced communication skills) have to be met together with at 
least 5 of the 11 supportive criteria (breathing irregularities, air swallowing 
bruxism, kypho-scoliosis, abnormal gait, lower limb amyotrophy cold, purplish 
feet, diminished response to pain, sleep disturbances, laughing/screaming spells 
and intense eye contact). 
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Table1. Rett syndrome diagnostic criteria 2010 (Neul et al., 2010) 
Consider RTT diagnosis when postnatal deceleration of head growth is 
observed 
Required for typical or classic RTT 
A period of regression followed by recovery or stabilization 
1. All main and all exclusive criteria 
2. Supportive criteria are not required, although often present in typical 
RTT 
 
Required for atypical or variant RTT 1. A period of regression followed by recovery or stabilization 2. At least 2 of 4 main criteria 3. 5 out of 11 supportive criteria 
Main criteria 
1. Partial or complete loss of acquired purposeful hand skills 
2. Partial or complete loss of acquired spoken language 
3. Gait abnormalities: impaired (dyspraxia) or absence of ability 
(apraxia) 
4. Stereotypic hand movements such as hand wringing/squeezing, 
clapping/tapping, mouthing and washing/rubbing automatisms 
 
Exclusion criteria for typical RTT 
1. Brain injury secondary to trauma (peri- or postnatally), 
neurometabolic disease or severe infection that cause neurological 
problems 
2. Grossly abnormal psychomotor development in the first 6 months of 
life 
Supportive criteria for atypical RTT 
1. Breathing disturbances when awake 
2. Bruxism when awake 
3. Impaired sleep pattern 
4. Abnormal muscle tone 
5. Peripheral vasomotor disturbances 
6. Scoliosis/kyphosis 
7. Growth retardation 
8. Small cold hands and feet 
9. Inappropriate laughing/screaming spells 
10. Diminished sensitivity to pain 
11. Intense eye communication and eye-pointing behaviour  
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Table 2. The cardinal clinical features of Rett syndrome in relation to pathology 
(Julu et al., 2008) 
 
Affected part Reported pathology        Clinical observations 
Cortical  Decreased dendritic 
arborization and smaller 
than normal brain. 
Severe intellectual disability 
Cortical Epilepsy Seizures 
Extrapyramidal Monoaminergic dysfunction Dystonia, incoordination of 
motor activities, secondary 
orthopedic deformities, and 
muscle wasting with 
contractures 
Brainstem Monoaminergic dysfunction Dyspraxia, agitation and sleep 
disturbances 
Brainstem Immaturity with incompetence 
of ininhibitory neural networks 
Abnormal breathing rhythm 
and lack of integrative 
inhibitions are likely causes of 
sudden deaths 
Brainstem Dysautonomia Cold and blue extremities and 
sympatho-vagal imbalance 
 
RTT Variants and Differential Diagnosis 
 
The variant or atypical RTT in MeCP2-related disorder, in general, is referred to 
as “forme fruste” based on a more protracted clinical course with more preserved 
communicative and motor abilities. Other variant forms include: (a) the rare 
congenital variant (Rolando variant); the most severe form of atypical RTT, with 
onset of classic RTT features during the first three months of life. This variant is 
often caused by mutations in the FOXG1 gene (14q11-q13). (b) The late 
childhood regression form is characterized by a normal head circumference and 
by a more gradual and later onset (late childhood) regression of language and 
motor skills. (c) The preserved speech variant (PSD or Zappella variant) is 
marked by recovery of some verbal and manual skills and is often caused by 
mutations in MECP2. (d) The early onset seizure type (Hanefeld syndrome), 
characterized by seizures in the first months of life with subsequent development 
of RTT features. It is frequently caused by mutations in the X-linked CDKL5 
gene (Xp22).  CDKL5-associated clinical features can be briefly summarized in.  
(a) normal prenatal history; (b) irritability, drowsiness and poor sucking in the 
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perinatal period before seizure onset; (c) early onset epilepsy before 5 months of 
age; (d) Rett like features consisting of deceleration of head growth, stereotypies, 
poor to absent voluntary hand use, and sleep disturbances, and (e) severe 
intellectual disability with poor eye contact and language (Bahi-Buisson et al., 
2008; Hagberg & Skjeldal 1994; Neul et al., 2010). 
 
MeCP2 and RTT 
 
 
 
Figure 1: MECP2 gene and protein isoforms. Schematic illustration of the gene structure of 
MECP2 and the different domains of the two protein isoforms, MeCP2E1 and MeCP2E2. The 
primary amino acid composition of the N-terminus of MeCP2E1 and MeCP2E2 is depicted. 
                 (Zachariah & Rastegar 2012) 
The MECP2 Gene 
Classic RTT is a monogenic disorder caused by mutations in MECP2 encoding 
methyl-CpG-binding protein MeCP2 (Amir et al., 1999). This gene is located in 
the Xq28 region, and is the founding member of the MBP (methyl binding 
protein) family of proteins(Lewis et al., 1992; Meehan et al., 1992). Mutations in 
the coding region of this gene can be identified in 80% of patients with the 
clinical diagnosis. The genomic locus of MECP2 spans approximately 76 kb and 
consists of 4 exons encoding two different isoforms (MECP2E1 and MECP2E2), 
due to alternate splicing of exons (Figure 1). MECP2E1 isoform is expressed 
10X more in the brain as compared to the MECP2E2. MECP2 has a long highly 
conserved 3’UTR that has multiple polyadenylation sites. Alternative 3’ splicing 
leads to three different transcripts, short 1.8 kb and long 10 kb transcripts, with 
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the latter including a highly conserved  (8.5 kb) 3’UTR, and a third additional 
low abundance transcript of 5-7 kb length (Pelka et al., 2005). MeCP2 is a 
nuclear protein that mainly colocalizes with densely methylated heterochromatin 
in mouse cells. Mecp2/MECP2 transcripts are expressed differentially in 
different tissues and during different stages of development. In the brain, 
differential expression patterns are observed for the two MeCP2 isoforms 
(Dragich et al., 2007). The transcript levels are high during embryogenesis and 
decrease postnatally, but again increases during adulthood. On the contrary, 
protein levels are low during embryogenesis and increase postnatally upon 
neuronal maturation (Shahbazian et al., 2002b).  
MeCP2E1 and E2 isoforms differ only in their N-terminal sequences, and have 
common Methyl Binding Domain (MBD) and Transcriptional Repression 
Domain (TRD). Though it seems that they have considerably overlapping 
functional properties but subtle etiologically relevant nonredundant functions of 
each transcript can’t be ruled out. Differential expression pattern of the two 
transcripts has been observed in the developing mouse brain (Dragich et al., 
2007) but it is yet to be confirmed that whether a similar variation is observed at 
the protein level or not. Mutation analysis of RTT patients has shown that exon 1 
mutations can lead to severe RTT phenotypes. Some of these mutations do not 
seem to affect the transcription of MeCP2E2, suggesting that MeCP2E2 alone 
might not be able to compensate the loss of MeCP2E1. This idea was tested by a 
group that studied the RTT phenotype rescue capability by each isoform. They 
showed that MeCP2E1 alone is capable of compensating for overall MeCP2 
deficiency in mice, in a dose dependent manner. Though MeCP2E2 also 
achieved phenotypic rescue, the degree of rescue was significantly higher for 
MeCP2E1, even at lower dosage levels (Kerr et al., 2012). The results of this 
study suggest that two isoforms have both redundant and nonredundant 
functions.   
 
MeCP2 protein, interacting protein partners and posttranslational modifications 
MeCP2 protein has three functional domains, viz., the methyl binding domain 
(MBD), the transcriptional repression domain (TRD) and the C-Terminal 
Domain (CTD). The MBD of MeCP2 consists of 63 residues with 4 anti-parallel 
beta-sheets that generate a wedge shaped structure. The MBD facilitates binding 
to the methylated CpG dinucleotides with a preference for adjacent A/T rich 
motifs (Klose et al., 2005). MeCP2 can also bind to non-methylated sequences 
such as the four-way DNA junctions (Galvao & Thomas 2005). However, the 
role of MeCP2 as a transcriptional repressor is mostly mediated through its TRD 
domain. The TRD interacts with a corepressor mSin3A, which further recruits 
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HDAC1 and HDAC2 causing transcriptional repression. Thus MeCP2 acts as a 
link between DNA methylation and chromatin remodeling (Nan et al., 1998). 
The TRD domain also helps in the interaction of MeCP2 with c-SKI (Kokura et 
al., 2001), YY1 (Forlani et al., 2010) and YB1 (Young et al., 2005). The CTD of 
MeCP2 is believed to have important functions, as transgenic mice lacking this 
domain display many RTT phenotypes (Shahbazian et al., 2002a). This C 
terminal region has a WW binding domain important for the interaction of 
MeCP2 with splicing factors (Buschdorf & Stratling 2004). WW binding domain 
recognizes the proline residues of interacting ligands, and is characterized by the 
presence of 2 tryptophan residues  (W) that are separated by 20-22 amino acids. 
MeCP2 is expressed in a wide variety of tissues but with the highest expression 
level in brain. Expression studies in rodents, macaque, and humans have revealed 
a similar pattern of heterogeneous MeCP2 expression in brain (Zachariah & 
Rastegar 2012). The MeCP2 expression patterns in different brain regions 
follows the developmental maturation of the CNS, being expressed initially in 
the earliest developing structures such as brainstem and thalamus (Shahbazian et 
al., 2002b); (Braunschweig et al., 2004; Mullaney et al., 2004). In rodents, 
MeCP2 expression in the olfactory bulb precedes synaptogenesis (Cassel et al., 
2004; Cohen et al., 2003). MeCP2 expression is highest in neurons, with lower 
level of expression in glia (Ballas et al., 2009). Within neurons, MeCP2 
expression is lower in immature neurons and highest in postmitotic neurons 
(Kishi & Macklis 2004). This elevated level of MeCP2 in mature neurons is 
maintained throughout the adulthood, implying its role in postmitotic function. In 
fact, MeCP2 deficiency in neurons is shown to cause RTT-like neurological 
phenotype in mouse (Chen et al., 2001). Recently, the expression of MeCP2 in 
glial cells has been shown to be necessary for neuronal maintenance, and in 
another study, it rescued RTT phenotype in a mouse model (Lioy et al., 2011).  
The post-translational modification of MeCP2 is known to modulate its gene 
regulatory activity (Tao et al., 2009; Zhou et al., 2006). Phosphorylation of the 
serine 421 (S421) residue was the first post-translational modification (PTM) to 
be described in MeCP2 and was found to be induced by increased neuronal 
activity associated with influx of calcium ions. This phosphorylation event was 
therefore believed to be triggered by a CaMKII (Ca++/calmodulin-dependent 
protein kinase II)-reliant mechanism. Out of total 12 tissues tested, this PTM was 
found only in brain tissue, suggesting S421 phosphorylation to be solely a 
neuronal event (Zhou et al., 2006). This study also showed that MeCP2 S421 
phosphorylation alleviates the repression of the BDNF gene. Another study 
demonstrated MeCP2 pS80 to be dependent on neuronal calcium influx, similar 
to S421 (Tao et al., 2009). However, in contrast to S421, the S80 
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phosphorylation was negatively regulated by neuronal activity, suggesting 
alternative signaling between the residues in resting or depolarized neurons. 
Additionally, the phosphorylation of both S80 and S421 was found to decrease 
the association of MeCP2 at specific loci.  
 
 
MeCP2 functions 
 
MeCP2 has dual functions, working both as a transcriptional activator via 
interaction with CREB (Chahrour et al., 2008), and as a repressor observed in 
vitro caused by chromatin compaction and nucleosome clustering (Georgel et al., 
2003; Muotri et al., 2010; Skene et al., 2010). MeCP2 also functions as a linker 
histone in neurons, as its levels are as abundant as histone proteins (Skene et al., 
2010). This study showed that in a MeCP2 mutant brain the transcription level of 
repetitive elements in neurons is increased. Thus, it suggests that instead of 
acting as a gene-specific transcriptional repressor, MeCP2 suppresses spurious 
transcription of repetitive elements across the genome in a DNA methylation 
dependent manner, thereby reducing “transcriptional noise” (Muotri et al., 2010; 
Skene et al., 2010).  
MeCP2 has been classically described as a global transcriptional repressor (Nan 
et al., 1997). The ability of MeCP2 to bind with methylated DNA and its 
localization in murine pericentromeric heterochromatin led the researchers to 
conclude MeCP2 to be a methylated DNA binding transcriptional repressor 
(Lewis et al., 1992). MeCP2 is 100 times more abundant than MeCP1 in the 
nucleus, and it could bind both to the methylated and unmethylated DNA to 
repress transcription (Meehan et al., 1992). In contrast, another in vitro study 
showed that MeCP2 bound to the methylated promoters caused repression of 
target genes whereas it caused slightly enhanced transcription level when bound 
to the unmethylated promoters (Nan et al., 1997). 
MeCP2 also plays a role in RNA processing (Young et al., 2005). Role of 
MeCP2 in RNA splicing was indicated by its interaction with a RNA binding 
protein YB1 (Y-box binding protein) (Young et al., 2005). The same study 
demonstrated that MeCP2 itself can bind to RNA and regulate splicing in vivo. In 
addition, MeCP2 interaction with the transcriptional activator CREB1 has shed a 
light on its involvement in active transcription (Chahrour et al., 2008; Yasui et 
al., 2007).   
The role of MeCP2 in the CNS has been facilitated by the development of 
various mouse models and the study of known phenotypic effects of the disorder. 
In humans, neuronal development and synaptogenesis occur in the embryonic 
week 12 and 20 respectively (Marsh et al., 2008). The absence of MeCP2 during 
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this key stage of development may be responsible for the decrease in neuronal 
and overall brain size in RTT patients. Disruption in MeCP2 function might 
therefore interfere with neuronal maturation and synaptogenesis, culminating in 
abnormal development of CNS. Several studies have also confirmed the role of 
MeCP2 in the development of dendritic spines and dendritic arborization, 
eventually affecting the synaptic connectivity. These defects in dendritic 
morphology in MeCP2 mutants are likely to cause the cognitive impairments 
observed in RTT patients. 
 
MeCP2 RTT mutations 
The location of MeCP2 in the Xq28 region of X chromosome is an important 
aspect in the etiology of RTT (Quaderi et al., 1994). MeCP2 mutations in males 
cause severe infantile encephalopathy because of the complete absence of a 
functional MeCP2. In contrast, females being heterozygous for the mutation, 
because of the presence of Mecp2 in X chromosome, show less severe symptoms 
than males, since half of the cells express the mutant MeCP2 allele and the other 
half expressing the functional allele. Therefore, RTT syndrome is found almost 
exclusively in females. 
Genetic analysis has identified 218 mutations linked to RTT (Miltenberger-
Miltenyi & Laccone 2003). These mutations are spread in all the three domains, 
indicating that each domain has an important function. Usually these mutations 
are single point mutations that give rise to a missense or nonsense mutant 
resulting in either amino acid change or a truncated protein respectively. 
MeCP2 mutations are mostly sporadic, occurring preferentially as C>T 
transitions of CpG dinucleotides and mostly on the paternal X-chromosome 
(Girard et al., 2001; Trappe et al., 2001). MeCP2 mutations have been detected 
in more than 90% of classic RTT patients. Approximately 65% of MECP2 
mutations causing RTT are attributed to 8 recurrent missense or nonsense 
mutations within the MBD (R106W, R133C, T158M and R168X) or TRD 
(R255X, R270X, R294X and R306C) (Bienvenu et al., 2000; Schanen et al., 
2004)(94, 95). These mutations have been termed mutational “hotspots” 
(Kriaucionis & Bird 2004) and interestingly, most of these mutations occur at 
arginine residues. Though methylation specificity of MeCP2 is said to be 
important in the etiology of RTT syndrome, the two mutations in the MBD, i.e., 
T158M and R168X that have a weak or no affect on methylation affinity of the 
protein respectively, and other pathogenic non-MBD mutations support the idea 
that MeCP2 functions other than methyl-CpG binding are also crucial for a 
normal neurodevelopment.  
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At present, there is no effective treatment for RTT syndrome. However, recent 
studies in MeCP2 knockout mice showing RTT phenotype showed rescue 
symptoms after reactivation of MeCP2 (Giacometti et al., 2007; Guy et al., 
2007).  This demonstrates that delivering MeCP2 in neurons might be an 
effective gene therapy method for alleviating the RTT phenotype to some extent.  
 
 
CDKL5 and RTT 
 
The CDKL5 Gene  
The CDKL5 gene was identified by positional cloning study and mapped on the 
short (p) arm of the X-chromosome at location 22, i.e., Xp22 region. Sequence 
analysis studies revealed its homology to several other serine-threonine kinase 
genes and identified one protein signature specific to this subgroup of kinases, 
and hence, the gene was called STK9  (Serine Threonine Kinase; ref). By 
genomic analysis Montini et al., initially demonstrated that CDKL5 consists of 
20 coding exons (Montini et al., 1998). Later, three more exons were discovered, 
taking the total count of exons to 23 (Figure 2). The first three exons (1, 1a and 
1b) are untranslated and probably represent 2 transcription start sites of the gene. 
(Kalscheuer et al., 2003). The initiation codon is located within exon 2.   
 
 
 
Figure 2: The human CDKL5 gene with non-translated sequence in grey and exons encoding 
the catalytic domain in the blue. Exons encoding the common C-terminal region appears in 
white, whereas isoform specific sequences are shown in red, green and as hatched..  
                        (Kilstrup-Nielsen et al., 2012) 
 
Recently, an additional 123 bp exon was identified between exon 16 and 17; 
thus, by alternative splicing the two isoforms called CDKL5 exon 16b (Fichou et 
al., 2011) and CDKL5 exon 16a (Rademacher et al., 2011) are formed. Exon 16b 
has a very high degree of similarity between species, suggesting a functional role 
that has been maintained through evolution. Furthermore, transcript analysis 
studies have shown that the exon-16b containing mRNA isoform is specifically 
found in the brain (Fichou et al., 2011). In rats, two splicing isoforms of CDKL5 
named CDKL5a and CDKL5b have been identified, each having a length of 934 
and 877 amino acids respectively (Figure 3). CDKL5a isoform is expressed more 
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in pure neuronal cultures, and CDKL5b is the only isoform expressed in pure 
glial cultures, suggesting a role in gliogenesis (Chen et al., 2010). Moreover, the 
expression of a CDKL5 isoform with an alternative C-terminus that terminates at 
intron 18 has also been described by aligning the human and mouse CDKL5 
proteins to the orthologs of other species (Williamson et al., 2012). This novel 
isoform, i.e. CDKL5107, is the major CDKL5 transcript in the human brain and all 
other tissues investigated except the testis. 
 
       (a) 
        
        (b) 
Figure 3. Splice variants of CDKL5. (a) hCDKL5 protein isoforms differing in the C-terminal 
region. CDKL5115 contains the primate specific exons 19-21. In CDKL5107, intron 18 is 
retained. The inclusion of exon 16b would generate CDKL5115+ex. 16b and/or CDKL5107+ex. 16b . 
hCDKL5-ex19 is a hypothetical splice variant in which exon 19 is excluded generating an 
alternative C-terminus. (b) The murine CDKL5 isoforms. mCDKL5105 harbors a distinct C-
terminal region encoded by a mouse specific exon 19 (orange). As in humans, the retention of 
intron 18 generates the common CDKL5107 isoform.                (Kilstrup-Nielsen et al., 2012) 
The CDKL5 Protein 
As already mentioned, CDKL5 protein has different splice variants (Figure 3), 
the original transcript being 1030 aa long with an estimated molecular mass of 
115 kDa (Bertani et al., 2006). CDKL5 belongs to the CMGC family of 
serine/threonine kinases (including cyclin-dependent kinases (CDKs), mitogen-
activated protein kinases (MAP kinases), glycogen synthase kinases (GSK), and 
CDK-like kinases) and is characterized by an N-terminal catalytic domain (13-
297 aa), homologous to that of CDKL family members. CDKL5 is a unique 
member of this family because it has a remarkably long COOH-terminus, with 
more than 600 aa, usually not found in CDKL proteins, and evolutionarily 
conserved in different orthologs. 
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Initially, sequence analysis indicated that CDKL5 is a proline directed 
serine/threonine kinase closely related to p56 KKIAMRE (the protein encoded 
by CDKL2) and p42 KKIALRE (the protein encoded by CDKL1), which share 
homology with the members of mitogen-activated protein (MAP) kinase and 
cyclin-dependent kinase-like  (CDKL) protein families (Montini et al., 1998). 
The sequence alignment of CDKL5 with these homologs showed 2 kinase 
signatures in the catalytic domain: (a) an ATP binding site (aa 14-47) and (b) a 
serine-threonine protein kinase active site (aa 127-144) (Figure 4). In addition, 
the catalytic domain has a conserved Thr-X-Tyr (TXY) sequence that 
corresponds to the TXY activation motifs of classic MAP kinases such as ERK2. 
Dual phosphorylation of this TEY motif is involved in activating, among others, 
kinases of the MAP kinase family. 
 
Figure 4: Schematic illustration of CDKL5. Full length human CDKL5115 is 1030 aa long and 
contains an ATP binding site, the serine-threonine (ST) kinase active site and the conserved 
Thr-Xaa-Tyr (T-X-Y) motif within the catalytic domain. A putative signal peptidase I serine 
active site, 2 supposed nuclear localization signals and one supposed nuclear export signal are 
indicated. The number at the top refers to the amino acid positions. 
 
The long C-terminal (297-1030 aa) of CDKL5115 has regulatory functions. In 
fact, this tail acts as a negative regulator of the catalytic activity of CDKL5, and 
through its putative signals for nuclear import (NLS) and export (NES) it 
modulates the subcellular distribution of CDKL5 (Bertani et al., 2006). A 
putative signal peptidase I serine active site (GTSMCTPL) is located between 
amino acids 971 and 978.  
CDKL5 has two splice variants with distinct 5’UTRs: isoform I, containing exon 
1, is transcribed by a wide range of tissues, whereas isoform II, including exons 
1a and 1b, is expressed only in testis and fetal brain (Kalscheuer et al., 2003) 
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(Williamson et al., 2012). Alternative splicing gives rise to at least three 
hCDKL5 isoforms. The original CDKL5 transcript is 1030 aa long  (CDKL5115; 
115 kDa). While CDKL5115 is mainly expressed in testis, two recently identified 
transcripts are likely to be relevant for CDKL5 brain functions (Williamson et 
al., 2012).  
     
         (a)     
 
(b) 
 
Figure 5: CDKL5 molecular structure and its pathogenic mutations. (a) Schematic representation 
of CDKL5115 with its functional domains and signatures. NLS: nuclear localization signal; NES: 
nuclear export signal. (b) All mutations reported in CDKL5 to date are indicated. Mutations 
shown above CDKL5 generate deletion and frameshift derivatives, as well as splice variants 
indicated with the cDNA nomenclature. Missense and nonsense mutations (fuchsia and black, 
respectively) are represented with the amino acid nomenclature below the CDKL5 gene.              
*: recurrent mutations,           o: uncertain pathogenicity. 
                       (Kilstrup-Nielsen et al., 2012) 
 
Fichou et al., 2011). This CDKL5107 isoform, with alternative C-terminus and 
terminating at intron 18, is the most predominant form expressed in the brain, 
and is expressed in many species, along with human and mouse, rendering 
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CDKL5 mouse model of relevance for studying CDKL5 functions (Williamson 
et al., 2012). Interestingly, an alternative splice variant, containing another 
distinct C-terminus, has been predicted through bioinformatics simulation (EC 
gene analysis). 
Cdkl5 is expressed in many tissues but with the highest level of expression in 
brain (cerebral cortex, hippocampus, cerebellum, striatum and brain stem), 
followed by testes and thymus (Lin et al., 2005). Its expression levels and 
subcellular distribution vary during the different developmental stages and in 
different brain areas (Rusconi et al., 2008). CDKL5 expression is low in 
embryonic cortex and is strongly increased during the perinatal and postnatal 
stages in maturing neurons in both cerebral cortex and hippocampus suggesting a 
role in neuronal maturation (Rusconi et al., 2008). Significant amounts of 
CDKL5 have also been found in the dendrites of cultured primary cortical 
neurons. The subcellular distribution on CDKL5 is controlled by an active 
cytoplasmic export mechanism together with and a nuclear import mechanism 
(Rusconi et al., 2008). The entry of CDKL5 into the nucleus depends on two 
NLS-like stretches (aa 312-315 and aa 784-789) of basic amino acids within the 
tail of the protein, whereas the cytoplasmic localization depends on an active 
nuclear export mediated by CRM1 nuclear export receptor (Rusconi et al., 2008).  
 
CDKL5 mutations  
The overall frequency of CDKL5 mutations in females with the early-onset 
seizure variant of RTT is around 8-16% (Bahi-Buisson et al., 2008b; Nemos et 
al., 2009 (Mei et al., 2010). In females having both early onset seizure and 
infantile spasms this mutation rate raises to 28% (Bahi-Buisson et al., 2008b). 
Till now almost 100 patients have been described with different CDKL5 
mutations, including missense and nonsense mutations, small and large deletions, 
and frameshift and aberrant splicing alterations (Fig. 5). Although  a small 
number of cases have been described so far, still hot-spots have been suggested 
for few mutations (indicated with an asterisk in Fig. 5b).  
Missense mutations are mainly localized in the catalytic domain, thus confirming 
the relevance of the kinase activity of CDKL5 for proper brain function and/or 
development. These missense mutations in the catalytic domain can cause 
impairment in auto-phosphorylation and phosphorylation of target proteins, such 
as MeCP2 (Bertani et al., 2006; Tao et al., 2004). On the contrary, truncating 
mutations have been found all across the gene, both in the catalytic domain and 
the C-terminal tail, possibly leading to CDKL5 derivatives of various lengths. 
Though, so far, no report has shown the existence of truncated CDKL5 protein in 
patients’ cells, the molecular effects of some of these pathogenic mutations 
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(missense and truncating derivatives in the background of CDKL5115 isoform) 
have been shown by overexpressing these mutated derivatives in non-neuronal 
cell lines (Bertani et al., 2006; Lin et al., 2005; Rosas-Vargas et al., 2008). From 
these studies C-terminus appeared to act as a regulator of CDKL5 functions. 
Indeed, its truncations led to increased catalytic activity and also controlled its 
sub-cellular localization (Bertani et al., 2006; (Rusconi et al., 2008). Truncated 
CDKL5 derivatives had, in fact, been found to localize more in the nucleus; in 
particular, the pathogenic derivatives L879X and R781X appeared exclusively 
confined to the nucleus, whereas the full-length protein is equally distributed 
between the two compartments. Interestingly, as the leucine-rich Nuclear Export 
Signal-like motif, shown in figure 5a, is preserved in the L879X derivative, such 
motif seems to be insufficient for driving CDKL5 into the cytoplasm. Whether 
truncated CDKL5 acts as a loss- or gain-of function protein still remains to be 
understood; in fact, if expressed, they would be mislocalized hyperfunctional 
derivatives and we still do not know whether the lack of a functional CDKL5 in 
the cytoplasm or the presence of an hyperactive kinase in the nucleus, or both, 
result in the pathogenic phenotype. It is however important to recall that 
pathogenic duplications of the X-chromosome, including CDKL5, have also been 
reported showing RTT like features (ref). In the future it will be thus important to 
address whether an optimal CDKL5 level is important for the development and 
functioning of the central nervous system.   
 
Genotype-phenotype correlation 
At present, there are no conclusive data suggesting the existence of a genotype-
phenotype correlation for CDKL5 mutations. Some reports suggest that 
mutations affecting the N-terminal catalytic domain are associated with more  
severe phenotype consisting of early onset and intractable infantile spasms 
followed by late onset multifocal myoclonic epilepsy (Bahi-Buisson et al., 
2008a), with respect to mutations in the COOH-terminus resulting in a milder 
phenotype (Russo et al., 2009). However,  these reports are debated, and 
generally the nature of mutations seems to not correlate with the clinical 
heterogeneity. This idea appears supported by a report in which two genetically 
identical CDKL5–mutated twin girls showed a significantly discordant 
phenotype (Weaving et al., 2004). In fact, one of the twins showed a clinical 
phenotype overlapping with RTT, while the other showed an autistic disorder 
with mild-to-moderate intellectual disability. Since both girls were characterized 
by random X-inactivation, it is thought that their phenotypic differences can be 
attributed to modifier genes that have been differentially induced by 
environmental and/or epigenetic factors. 
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Functions of CDKL5 protein 
Although we still do not know which and how many functions harbors CDKL5 
and which ones are relevant in the CDKL5-related pathologies, in the last years 
few publications have started to unravel the molecular activities of the kinase and 
the phenotypic consequences of its malfunctions in neurons. Herein, I will 
summarize the most relevant data.  
 
CDKL5 expression correlates with neuronal maturation and maintenance 
As already mentioned it is evident from earlier studies that CDKL5 expression 
correlates, both in vitro and in vivo, with neuronal maturation, reaching the 
highest level of expression when neurons acquire a mature phenotype, thus 
suggesting a role for CDKL5 in neuronal differentiation and arborization (Chen 
et al., 2010; Rusconi et al., 2011). Interestingly, even though CDKL5 expression 
levels decrease slightly in adult brain, they are significantly higher than in non-
neuronal tissues. Hence, CDKL5 might have a role in maintaining neuronal 
functions in addition to maturation. Furthermore, since, CDKL5 intracellular 
distribution changes upon neuronal maturation and its nuclear fraction peaks in 
adult brain, such fraction may be involved in adult brain synaptic plasticity. 
 
CDKL5 affects neuronal morphogenesis through cytoskeletal rearrangements 
In brain disorders, such as RTT and Fragile X, arborization defects disrupt 
experience dependent neuronal maturation and plasticity (Kaufmann & Moser 
2000).  In vitro, by RNAi and overexpression of CDKL5 in cultured rat neurons, 
Chen et al., showed that CDKL5 is a critical regulator of neuronal 
morphogenesis and dendritic arborization. In vivo, CDKL5 shows overlapping 
functions and affects neuronal migration (Chen et al., 2010). Interestingly, 
CDKL5 colocalizes with F-actin in the growth cone and interacts with Rac1. 
Rac1 is a protein that belongs to the Rho GTPase family and it promotes 
formation and/or maturation of spines by remodeling the actin cytoskeleton of 
neuronal spines (Tolias et al., 2011). Functional experiments suggested that 
CDKL5 influences neuronal morphogenesis by acting upstream of Rac1, and 
CDKL5 itself is activated by transient phosphorylation from brain-derived 
neurotrophic factor (BDNF). In the absence of CDKL5, BDNF is unable to 
activate Rac1 (Chen et al., 2010).  
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Neuronal stimuli affect CDKL5 function 
The knowledge of stimuli affecting CDKL5 expression might help in 
understanding how CDKL5 deficiency might impact brain functions. As already 
mentioned, the activity-regulated BDNF gene induces a transient 
phosphorylation of CDKL5 and this post-translational modification is required 
for Rac1 activation by BDNF (Chen et al., 2010). Furthermore, it has been 
demonstrated that CDKL5 is transported from the nucleus to the cytoplasm in 
response to the activation of extrasynaptic NMDA receptors (NMDA-R). After 
translocation, the kinase gets degraded (Rusconi et al., 2011). Recent 
publications suggest that extrasynaptic NMDA-R have a role in LTD and 
dephosphorylation of CREB; alterations in the cross-talk between synaptic and 
extrasynaptic receptor activities may play an important role in seizures 
(Hardingham & Bading 2010; Hardingham et al., 2002; Sierra-Paredes & Sierra-
Marcuno 2007). 
 
CDKL5 might regulate the functions of epigenetic factors and transcriptional 
regulators 
There is some evidence suggesting a role of CDKL5 in regulating gene 
expression. Previous studies have shown that the transcriptional repressor 
MeCP2 and CDKL5 work in the same molecular pathway, sharing overlapping 
temporal and spatial expression pattern in the brain, and both being activated 
simultaneously during neuronal maturation. According to the current 
understanding, CDKL5 works upstream of MeCP2 and causes its 
phosphorylation either directly or indirectly, thereby influencing its function 
(Bertani et al., 2006; Mari et al., 2005). Since several studies have shown that, in 
neurons, MeCP2 acts as a dynamic epigenetic factor, regulating gene 
transcription during learning and memory through activity–dependent 
phosphorylation of specific serine residues (Chen et al., 2003; Martinowich et al., 
2003; Tao et al., 2009; Zhou et al., 2006), it is possible to assume that in the 
absence of CDKL5, a specific phosphorylation dependent activity of MeCP2 
might be altered causing a subset of Rett symptoms.  
The connection of CDKL5 to epigenetics and gene expression appears 
strengthened by an article showing its interaction with DNMT1; it is interesting 
to recall that inhibition of DNA methyltransferase I (DNMTI) in the 
hippocampus affects contextual fear memories and LTP (Day & Sweatt 2011). 
Eventually, CDKL5 expression is induced by MeCP2 ablation, DNMT 
inhibition, and histone deacetylase inhibition (Carouge et al., 2010).  
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CDKL5 controls signal transduction pathways and event-related potentials 
whose disruption leads to austistic features 
 
A recently developed CDKL5 KO mouse model has reaffirmed the role of 
CDKL5 for proper brain functioning by showing autistic like features (Wang et 
al., 2012). Furthermore, exploiting this mouse model, the authors have performed 
a serine/threonine kinome study and have revealed that many signal transduction 
pathways are disrupted.  Interestingly, many of these pathways, including the 
AKT-mTOR pathway that appears down-regulated in the Cdkl5-null brain, have 
been implicated in the etiology of ASDs (Jeste et al., 2008; Tsai et al., 2012). 
Since mTOR is known to regulate cell growth, proliferation, motility and neural 
plasticity (Zoncu et al., 2011), any reduction in the AKT-mTOR activity, due to 
the absence of CDKL5, may lead to disruption of neuronal development. As 
mentioned, RNAi mediated knockdown of CDKL5 results in impaired dendritic 
outgrowth, neuronal migration (Chen et al., 2010), and spine maturation 
(Ricciardi et al., 2012); in the future it will be interesting to study whether the 
observed phenotype is linked to the down-regulated pathway. 
Furthermore, Cdkl5-/y mice showed decreased phosphorylation profile of kinases 
involved in synaptic plasticity, including PKA, PKC, and protein kinase D 
(PKD), as well as kinases involved in  cellular metabolism, including AMPK, 
ATM/ATR, and casein kinase (CK) (Wang et al., 2012). 
 
CDKL5 influences dendritic spine development 
 
Very rcently CDKL5 has been found to co-localize with the post synaptic density 
(PSD) of excitatory synapses both in vivo and in vitro (Ricciardi et al., 2012). 
Depletion of CDKL5 in rat hippocampal neurons indicated that CDKL5 is 
required for ensuring a correct number of well-shaped spines. These 
morphological alterations were associated with a reduction in the number of 
excitatory synapses and a significant decrese in spontaneous miniature excitatory 
postsynaptic currents (mEPSCs). However, there was  no significant effect on 
inhibitory synapse density or any significant changes in miniature inhibitory 
postsynaptic currents (mEPSCs) (Ricciardi et al., 2012). CDKL5 also interacts 
with and phosphorylates Netrin G1 receptor (NGL-1). NGL-1 is a synaptic cell 
adhesion molecule which plays an important role in early synapse formation and 
subsequent maturation. NGL-1 binds with PSD95, a protein that plays an 
important role in learning and memory, and this binding is stabilised by 
phosphorylation of NGL-1 at Ser631 by CDKL5. This stabilisation of NGL-
1/PSD95 helps in the targeting of  PSD95 to new forming dendritic protrusions 
(Ricciardi et al., 2012). Summarizing the data, at least two important pathways 
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are associated with the cytoplasmic functions of CDKL5: Rac-1 and BDNF and, 
PSD95 with the NGL-1 complex.  
 
CDKL5 binds with and phosphorylates amphiphysin 1 
Amphiphysin is a novel substrate that has been found to interact with and get 
phosphorylated by CDKL5 at Ser-293. Again this mechanims occurs in the 
cytoplasm highlighting the relevance of the cytoplasmic portion of CDKL5; 
importantly, this phosphorylation is disrupted by mutations in the catalytic 
domain of CDKL5 (Sekiguchi et al., 2013). Phosphorylation of Amph1 by 
CDKL5 is found to be significantly higher than those of MeCP2 and Dnmt1. 
Amph1 is abundantly present in the cytoplasm and is highly expressed in 
neurons. Amph1, a mutlifunctional adaptor protein, plays an important role in 
neurotransmission and synaptic vesicle recycling through clathrin-mediated 
endocytosis (Wigge & McMahon 1998); accordingly, Amph1 deficient mice 
show major learning difficulties and irreversible seizures, suggesting its role in 
neural development and transmission (Di Paolo et al., 2002).  
To conclude, although the identification of novel interactors and phosphorylation 
targets of CDKL5 will help in defining the neuronal functions of this kinase and 
the consequences of its deficiency, from the data obtained so far we can assume 
that the protein has a major role in synaptic formation,  activity and plasticity.  
 
Midbody  
 
As we will show in the Results section,  we have found that, in dividing Hela 
cells, CDKL5 localizes at the midbody, a transient structure that is formed during 
the late stages of mitosis. In the recent years the midbody has gained attention as 
new pathways and functions have been attributed to this structure, mainly the 
cytokinetic functions and some post-mitotic functions. In accordance with its role 
in abscission, mass spectrometry assays have shown that the midbody contains 
cytoskeleton proteins as well as other proteins involved in lipid rafts and vesicle 
trafficking (Skop et al., 2004). The midbody in animal cells is analogous to the 
cell plate present in plant cell division (Flemming 1891, Paweletz 2001) as both 
are composed of antiparallel microtubules with vesicles and amorphous electron-
dense material centrally positioned. 
 
Midbody structure and formation 
Midbodies (MBs) were first studied and reported by Walther Fleming using 
histochemical methods (Flemming, 1891). Since its first description, it has been 
studied sporadically by cytologists (Buck & Tisdale 1962; Mullins & Biesele 
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1977; Mullins & McIntosh 1982; Saxton & McIntosh 1987). Its formation begins 
when the midzone – a bipolar antiparallel microtubule array that assembles 
between separating sister chromatids during anaphase (also called the central 
spindle), undergoes compaction during the final stages of cytokinesis, giving rise 
to a tightly packed structure with a central bulge and adjacent filaments, covered 
by a membrane. There is a positive correlation between the conversion of 
midzones to midbodies and cytokinetic furrow ingression This is evident from 
the fact that blocking furrow ingression results in accumulation of cells that are 
stuck in midzone assembly (Straight et al., 2003). Hence, furrow is believed to 
compact the antiparallel midzone MTs into a single large bundle that comprises 
the core of the MB (Fig 6a). 
 
MB attains final structure by late cytokinesis and has three components – (a) the 
central core (also called stem body), (b) flanking MTs and associated organelles, 
and (c) the surrounding plasma membrane (Figure 6a). The central core has two 
components, the ‘MB matrix’ and ‘MB ridges’. The MB matrix is mainly 
composed of antiparallel MT bundles and interspersed electron-dense material 
(Brinkley & Cartwright 1971; Kuo et al., 2011; McIntosh & Landis 1971; 
Mullins & Biesele 1977; Paweletz 1967). MB ridges surrounding the matrix 
account for the bulges within the intercellular bridge (Figure 6b) and is mainly 
composed of electron-dense material, a specialized thickening under the plasma 
membrane, and a few MTs (Mullins & Biesele 1977). MB ridges are likely to 
correspond to MB rings (MRs), donut shaped structures. 
 
Fate of post-mitotic midbodies 
Post mitotic MBs may have different fate depending on the cell type and status. 
Immediately after the abscission the post-mitotic MB is retained by one of the 
two daughter cells, connected to the cell body through a thin bridge, also known 
as tether. This tether can retract, delivering the post-mitotic MB into the 
cytoplasm of the daughter cell where it undergoes degradation or normal 
retention (Gromley et al., 2005; Ettinger et al., 2011; Kuo et al., 2011; Pohl & 
Jentsch 2009). Alternatively, the tether can be severed by the cell, releasing the 
post-mitotic MB into the extracellular space (Guizetti et al., 2011; Dubreuil et 
al., 2007; Elia et al., 2011; Ettinger et al., 2011), where it remains or is engulfed 
by a cell. These findings indicate that the fate determination of post-mitotic MBs 
involves multiple steps that might be tightly regulated, and is far different from 
their fate as residual bodies  as thought earlier (Guizetti et al., 2011; Mullins & 
Biesele 1977). 
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Figure 6: (a) Midzones between separated sister chromatids gradually convert into the 
midbody during furrow ingression. Individual midzone bundles are compacted into a single, 
large, midbody MT (microtubule) bundle. A bulge like structure named stembody is formed at 
the centre of midbody. The midzone, midbody and stembody are indicated in yellow. (b) 
Electron micrograph of MB shown in top panel. A comparable stage with corresponding 
differential-interference contrast (DIC) microscope image is shown in the middle and bottom 
panel, respectively. At the centre is the electron-dense MB core (top), which composes ‘MB 
ridges’ and ‘MB matrix’. The MB ridges (arrowheads; top) correspond to the MB ring (MR) 
on immunofluorescence and bulge on DIC microscopy (arrows; bottom). The MB matrix, by 
contrast, contains many antiparallel microtubules and electron dense material.                                                        
                                                                (a) Chen et al., 2013 (b) Hu et al., 2012 
 
(a)	  
(b)	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MB functions 
Abscission 
The most important function attributed to the midbody is to localize abscission. 
Recently, significant progress has been made in understanding the mechanisms 
of both abscission and the subsequent midbody breakage. The development  of 
midbody proteome (Skop et al., 2004) has lead to the discovery of a large 
number of molecules and pathways that contribure to abscission. These pathways 
include vesicle trafficking, membrane scission, MT severing and ubiquitination. 
Abscission may be carried out by the endosomal sorting complex required for 
transport (ESCRT) machinery and midbody breakage by the activity of 
microtububle-severing proteins (Elia et al., 2011; Gromley et al., 2005; Guizetti 
et al., 2011; Lee et al., 2008; Morita et al., 2007). However how ESCRT 
machinery and severing proteins are localized and temporally regulated is 
unknown. One problem in analysing the proteins in midbody assembly and 
abscission is that most of the midbody proteins are also required for furrow 
ingression; thus, their ablation causes earlier defects that preclude analysis of 
their subsequent specific roles. 
 
Non-cytokinetic functions  
Recent studies have suggested that midbodies may have non-cytokinetic 
functions too, such as polarity specification (Pollarolo et al., 2011; Wilcock et 
al., 2007), intercellular communication (Dubreuil et al., 2007; Marzesco et al., 
2005) and cell fate determination. In relation to the role of midbody in polarity 
specification, it is important to mention here that neuronal polarization may lead 
to some neuropsychiatric disorders autism, epilepsy, mental retardation and 
scezophrenia (Li et al., 2011). 
In the fly notum and chick spinal chord, post mitotic MBs of neurons were found 
to be present at the polarized/apical domain from where the future neurite or 
apical process sprouted (Pollarolo et al., 2011; Wilcock et al., 2007). Hence, this 
result suggested that post-mitotic MBs might specify neuronal polarity. Post-
mitotic MBs have been implicated in intercellular communication, presumably to 
maintain a balance between differentiating cells and progenitors (Dubreuil et al., 
2007; Marzesco et al., 2005). This hypothesis is based on the fact that MB 
release into the ventricle lumen increases significantly after neurogensis 
(Dubreuil et al., 2007; Marzesco et al., 2005).  
Furthermore, recent studies have shown that experimental manipulation of MB 
clearance can cause cell fate conversion. For example, inhibition of MB 
clearance/release could sensitize oligopotent neural progenitors to differentiate 
	   28	  
into neurons. On the contrary, terminally differentiated fibroblasts revert back to 
iPSCs on retention of MB (Ettinger et al., 2011; Kuo et al., 2011). Here, 
contradictarily MB retention results both in differentiation and dediferentiation 
of cells which may be because the modulator, presumably the MB, is itself 
modified in different ways.  
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      EPERIMENTAL PROCEDURES 
 
 
Plasmids 
The three plasmids, viz., GFP-wt-CDKL5, GFP-CDKL5-N-terminal and GFP-
CDKL5-C-Terminal used for transfection of HeLa cells were made as explained 
by Bertani et al (Bertani et al., 2006). 
 
Antibodies 
 The following antibodies were used for western blotting and 
immunofluorescence experiments: polyclonal anti-GAPDH (Open Biosource), 
monoclonal anti-alpha-tubulin (Sigma), polyclonal anti-CDKL5 (Sigma), 
monoclonal anti-phospho aurora A/B/C (Cell Signalling), monoclonal anti-AKT 
(Cell Signalling), polyclonal anti-Tsg101 (Abcam), polyclonal anti-Cep55 
(Abnova), polyclonal anti-Ect2 (Santa Crus), polyclonal anti-IQGAP1 (Santa 
Cruz), polyclonal ant-GFP (Molecular Probes). 
 
Cell cultures and transfections 
Cell cultures and transfections: human HeLa cells and MRC5 were maintained in 
Dulbecco’s modified Eagle’s medium (D-MeM) supplemented with 10% foetal 
bovine serum, 2mM L-Glutamine and 100 U/mL Penicillin-Streptomycin and 
grown at 37°C with 5% CO2. Neuroblastoma Neuro-2a cell line was maintained 
in MeM supplemented with 10% foetal bovine serum, 1% non-essential 
aminoacids, 2mM L-Glutamine and 100 U/mL Penicillin-Streptomycin and 
grown at 37°C with 5% CO2. 
 
Low-density primary cultures of cortical neurons were prepared from brains of 
mouse embryos at 18 days (E18). Cortex was removed, centrifuged at 800g, 
washed twice in HBSS (GIBCO) and dissociated by a 15’ incubation in 0.25% 
trypsin (Sigma) at 37°C. Suspended cells were plated at a density of 20’000-
30’000 cells/cm2 on poly-D-lysine (50g/mL, Sigma) coated glass coverslips in D-
MeM with 10% horse serum and 2mM L-Glutamine. After 3-4 hours, coverslips 
were transferred in a dish containing a monolayer of cortical astrocytes without 
physical contact between neurons and glial cells. Neurons were grown in glial 
conditioned Neurobasal (Gibco) medium with B27 supplement (GIBCO) and 
2mM L-Glutamine and incubated at 37°C with 5% CO2. After 3 days in vitro 
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(div), cytosine-1-b-D-arabinofuranoside (Ara-C, Sigma) at the final 
concentration 2 mM was added to prevent astroglial proliferation. 
 
Immunofluorescence 
Cortical neurons were fixed at 4 days in vitro (DIV) by 4% PFA, cells were 
washed and subjected to immunofluorescence. After 10 minutes in 
permeabilization buffer (20mM HEPES pH 7.4; 300mM sucrose; 3mM MgCl2; 
0.2% Triton X-100 and 50mM NaCl), aspecific sites were saturated by a 
blocking solution (5% FBS in PBS) for 30 minutes and fixed neurons were 
incubated overnight at 4°C with primary antibodies in 5% FBS and 0.1% Triton 
X-100. The following day, cells were rinsed in PBS 3 times and incubated with 
the secondary antibodies (anti-rabbit Alexa Fluor 555 and anti-mouse Alexa 
Fluor 488, Invitrogen) in blocking solution for one hour. Finally, nuclei were 
stained with DAPI and the specific signals were analysed. 
 
Untransfected cells: HeLa cells cultured on glass coverslips were washed in PBS 
and fixed with 2% PFA in PBS at room temperature for 10 minutes. After 
permeabilization with 0.2% Triton in PBS for 6 hours, cells were blocked in 5% 
BSA in PBS with 0.2% Triton X-100 for 1 hr. The fixed cells were stained with 
the indicated primary antibodies in the same blocking solution overnight at 4oC. 
Next day, cells were washed with PBS and incubated for 1 hour with the 
appropriated secondary antibodies at room temperature. After three PBS washes 
nuclei were stained with DAPI (Sigma) and mounted using Prolong Gold 
Antifade medium (Life Technologies). and the specific signals analysed with a 
Nikon Eclipse Ni fluorescence microscope.  
 
Transfected HeLa cells: HeLa cells were seeded on glass coverslips and 
transiently transfected with GFP-tagged CDKL5 constructs using Lipofectamine 
2000 (Invitrogen). 16-18 hours post-transfection, the cells were permeabilized 
(0.2% Triton in PBS for 2 minutes), fixed in 2% paraformaldehide (PFA) for 10 
min, and blocked with blocking medium (5% BSA/ 0.2% Triton X-100/ PBS) for 
1 hr. Then cells were stained with anti-GFP polyclonal and anti-alpha-tubulin 
monoclonal antibodies followed by secondary antibodies. Nuclei were stained 
with DAPI (Sigma) and the specific GFP-signals analysed with a Nikon Eclipse 
Ni fluorescence microscope.   
 
Silencing experiments: HeLa cells were transfected with CDKL5 or scramble si-
RNA   24 hours after plating using oligofectamine (Invitrogen) reagent following 
manufacturer’s instructions. 72 hrs after the transfection, cells were scrapped for 
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immunoblot analysis and were subjected to immunofluorescence (refer IF 
protocol of untransfected cells).  
 
siRNA 
siRNA oligomers containing 19 nucleotides were synthesized using human 
CDKL5 sequence 5’-CUAUGGAGUUGUACUUAAA-3’ (Thermo Scientific). 
The selected sequence was submitted to a BLAST search against the mouse 
genome, to ensure that only the CDKL5 gene was targeted. si-scramble non 
targeting siRNA (Thermo Scientific) was used as a control oligonucleotide.  
 
Wound Healing assay 
30,000 HeLa  cells were seeded on a glass coverslip in a 6 well plate followed by 
transfection with si-scramble and si-CDKL5 oligos the next day. After 3 days of 
transfection, scratch wounds were made using a pipette tip and medium was 
changed to remove debris and mitotic cells. Cells were fixed at different time 
points, i.e., 0 and 24 hrs, followed by immunofluorescence.  
 
Midbody isolation 
HeLa cells were enriched in telophase by treatment with Nocodazole (100ng/ml 
for 4 hrs) followed by mitotic shake off, nocodazole washout and incubation of 
the collected cells for about 60 min. to reach telophase stage. Midbodies were 
isolated as described by Rinaldo et al (Rinaldo et al 2012) and extracted using an 
extraction buffer (50mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% SDS, 0.5% NP-
40, 5 mM EDTA) supplemented with protease- and phosphatase-inhibitor mix 
(Roche). TCEs (Total cell extracts) from asynchronized interphase cells were 
obtained in the same manner and analyzed by WB together with midbody 
extracts. 
 
Coimmunoprecipitation assay  
Midbody lysate was prepared from HeLa cells in lysis buffer (50mM Tris-HCl 
pH 7.4, 150 mM NaCl, 0.1% SDS, 0.5% NP-40, 1 mM DTT, 5 mM EDTA) 
supplemented with protease- and phosphatase-inhibitor mix (Roche). The lysates 
was incubated with anti-CDKL5 polyclonal antibody (Invitrogen) overnight at 
4oC. The immunocomplex was then incubated with 50% rG-agarose beads 
(Invitrogen) blocked with 5% BSA for 1hr at 4oC. The complexes bound to the 
beads were eluted by resuspending in Laemmli reducing sample buffer followed 
by heating at 90oC for 5 min. The immunocomplex was subjected to SDS-PAGE, 
followed by immunoblotting with the indicated antibodies. 
  
 
	   32	  
 
 
 
     Results 
 
CDKL5 localizes at the centrosome and midbody during mitosis in HeLa 
cells and in the centrosome of post-mitotic cortical neurons 
While working on MeCP2 in our lab we found that MeCP2 localizes at the 
centrosome during early mitotic phase (Bergo et al., submitted for publication) in 
HeLa cells (Figure 7). Since it is known that MeCP2 and CDKL5 belong to the 
same molecular pathway (Mari et al 2005) and have a similar spatio-temporal 
localization pattern we decided to investigate the localization of CDKL5 during 
mitosis in dividing cells. We observed that similarly to MeCP2, also CDKL5 
localizes at the spindle poles during early mitosis. However, in contrast to 
MeCP2 which remains present at the spindle poles throughout the mitosis, 
CDKL5 leaves the poles and starts localizing at the midzone during late 
anaphase, and localizes completely at the midbody during telophase till 
abscission (Figure 8a and b). As the cell enters interphase, CDKL5 acquires 
again its canonical nuclear punctate staining and does not show any co-
localization with the centrosome.   
 
Considering that MeCP2 deficiency mainly affects the CNS, we also studied 
whether MeCP2 localizes at the centrosome of mouse cortical neurons (DIV4). 
We found that similar to HeLa cells where MeCP2 is present at the centrosome 
during interphase in addition to mitosis, MeCP2 localizes at the centrosome of 
post-mitotic neurons (Figure 9a). Surprisingly, although CDKL5 does not 
localize at the centrosome of dividing cells, it was revealed at the centrosome of 
post-mitotic mouse cortical neurons (DIV4) (Figure 9b).  
Next, we confirmed CDKL5 localization at the midbody by means of a 
biochemical approach. To this purpose we adapted a protocol from Rinaldo et al 
(Rinaldo et al 2012), as shown in the flowchart (Figure 10 a). Different markers 
were used to test the quality of the MB preparation. Phospho-aurora-A/B/C and 
alpha-tubulin confirmed enrichment of MB proteins whereas AKT and GAPDH 
were used to monitor the level of nuclear and cytoplasmic contamination 
respectively. From the same midbody fraction, both WB and 
immunofluorescence were performed (Figures 10b and c).  
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Exogenous CDKL5 is targeted to the midbody 
To confirm CDKL5 localization at the midbody and to identify the involved 
protein domains, we transfected HeLa cells with GFP tagged wt-CDKL5 and 
performed an immunofluorescence, aimed at revealing whether the exogenous 
protein gets also localized at this cellular structure. As shown in Fig. 11a, 
exogenously expressed GFP-CDKL5 localizes at the midbody ring as the 
endogenous CDKL5. Further confirmation was obtained through the above 
described biochemical assay performed on GFP-CDKL5 transfected HeLa cells 
(Figure 11b). HeLa cells transfected with a GFP expressing plasmid was used as 
a negative control. A GFP positive signal of approx. 140 kDa confirmed the 
presence of GFP-CDKL5 in the midbody fraction of HeLa cells while the GFP 
alone showed no signal, confirming specificity of the result.  
Altogether our data confirm the presence of endogenous and exogenously 
expressed CDKL5 at the midbody. 
 
N-terminal domain of CDKL5 is responsible for the midbody localization 
After the confirmation of exogenously expressed CDKL5 in the midbody, we 
decided to investigate the domain of CDKL5 responsible for this localization. 
For this purpose we used two different truncation derivatives, respectively 
characterized by the lack of the kinase catalytic domain (GFP-CDKL5-C-ter) or 
the long C-terminal domain (GFP-CDKL5-N-ter), along with the wt control, 
GFP-CDKL5 (Figure 12). These constructs were transiently overexpressed in 
HeLa cells and their midbody localization was analyzed by a biochemical assay. 
Midbody fraction along with total cell extract from interphase cells of each 
transfected plasmid were prepared and analyzed by western blot. We observed a 
GFP-CDKL5 signal in the midbody fraction of GFP-CDKL5 and GFP-CDKL5-
Nter but not in the GFP-CDKL5-Cter sample (Figure 13). The absence of signal 
in the MB fraction of GFP transfected cells confirmed the specificity of the 
result. Thus, we suggest that the N-terminal portion of CDKL5 is required for its 
MB localization. 
 
CDKL5 depletion causes mitotic defects and micronuclei formation 
We proceeded addressing whether a deficiency of CDKL5 causes any phenotype 
usually associated to the midbody. To this purpose, we silenced HeLa cells with 
si-CDKL5 and a si-scramble as a control and analyzed progression through 
mitosis. On silencing the CDKL5 gene we found mitotic defects in proliferating 
HeLa cells. The mitotic spindles of the CDKL5 silenced cells were elongated and 
“comet shaped” with irregular spindle arrangements (Figure 14a). Accordingly, 
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we measured a significant increase in the number of mitotic (Figure 14b) and 
multipolar cells (Figure 14c). 
 
It is known that mitotic spindle is essential for correct chromosome segregation, 
and centrosome abnormalities are often associated with chromosome instability. 
In some cases, centrosome impairment can lead to aberrant mitosis that leads to 
cell death following mitotic checkpoints; however we did not observe any 
significant increase in apoptosis in CDKL5 silenced HeLa cells (data not shown). 
In other cases, although cytokinesis occurs and daughter cells are viable, they fail 
cytokinesis and become binucleated (Figure 14d), as we found in CDKL5 
silenced HeLa cells. 
 
Due to the improper attachment of microtubules to chromosomes small, 
extranuclear bodies known as micronuclei are formed from lagging 
chromosomes during mitosis. Since we observed a defective spindle formation in 
CDKL5 silenced HeLa cells we decided to analyze the micronuclei formation by 
a quantitative analysis. As expected, we found an approximately 2-fold increase 
in the micronuclei formation (Figure 15a,b) in CDKL5 silenced HeLa cells as 
compared to the control.  
 
CDKL5-depletion causes defect in cell migration 
Since centrosomes and microtubule assembly and dynamics are important for 
cell motility  (Kodani and Sutterlin, 2008; Watanabe et al, 2005), we also 
analyzed the affect of CDKL5 depletion on cell migration. As above, HeLa cells 
were transfected with CDKL5 siRNA and scramble siRNA as a control. After 72 
hours of silencing, a wound was made on the evenly confluent monolayer and 
the kinetics of its healing was observed. After 24 hours of making the wound, 
HeLa cells transfected with the scramble-siRNA filled the wound by 67%. In 
contrast, CDKL5 silenced cells showed a significant delay in migration towards 
the wound (37% wound healing; Figure 16a,b). CDKL5 silencing was confirmed 
by western blotting (Figure 16c) 
 
CDKL5 interacts with IQGAP1, Cep55 and Tsg101 in the midbody 
Having demonstrated CDKL5 localization at the midbody, we consider of high 
relevance understanding which factor can target CDKL5 at the midbody or 
depend on CDKL5 for its specific localization. Interestingly, through a 
previously performed yeast two-hybrid screening we found that CDKL5 interacts 
with IQGAP1 (IQ-motif-containing GTPase activating protein), a scaffolding 
protein localized at the midbody (Skop et al 2004). Hence, we decided to confirm 
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IQGAP1 interaction with CDKL5. A coimmunoprecipitation assay from the 
midbody fraction of HeLa cells using an anti-CDKL5 antibody followed by 
immunoblotting was thus performed. As expected, we observed the interaction of 
CDKL5 with IQGAP1 in the midbody fraction. In the future we will have to 
confirm that IQGAP1 acts as a platform for the localization of CDKL5 at the 
midbody. 
 
Furthermore, considering that CDKL5 deficiency determines an increase in the 
number of multinucleated cells and defects in cytokinetic abscission, we 
analyzed whether a set of proteins involved in abscission interact with CDKL5 at 
the midbody. Using the same experimental setup as described above we 
performed a coimmunoprecipitation assay using the anti-CDKL5 Ab. Among the 
various proteins analyzed, we found Cep55 and Tsg101 to be interactors of 
CDKL5 at the midbody, whereas another protein Ect2 showed no coprecipitation 
(Figure 17). The presence of Cep55 and Tsg101 has already been published at 
the midbody; importantly, their absence has shown defects in abscission (Morita 
et al., 2007).  We speculate that CDKL5 interaction with Cep55 and Tsg101 at 
the midbody might have some role in facilitating abscission. 
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Figure	   7.	   In	   HeLa	   cells	   MeCP2	   (green)	   localizes	   at	   the	   spindle	   poles	   during	   early	  stages	   of	  mitosis,	   i.e.,	   till	   anaphase	   as	   shown	   by	   gamma-­‐tubulin	   staining	   (red),	   and	  then	   leaves	   the	   spindle	  poles.	  During	   interphase	   it	   shows	  a	  punctate	   staining	   in	   the	  nucleus.	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 Figure 8: (A) CDKL5 is present at the spindle poles, stained with y-tubulin (red), during early 
mitotic stages (I, II, III). From anaphase (IV), it starts localizing at the midzone. At telophase 
(VI) it is completely localized at the midbody. Finally, at interphase (VII) it forms speckles in 
the nucleus. (B) Immunofluorescence showing CDKL5 (green) at the midbody along with α-
tubulin staining the midbody filaments. 
 
  
A	  
B	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 Figure 9: Immunofluorescence staining of murine cortical neurons (DIV 4): In green, 
 MeCP2 (upper left panels) or CDKL5 (lower left panels); in red pericentrin (central 
 panels); on the right merged images. 	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Figure	   10.	   (A)	   The	   schematic	   diagram	  shows	   the	   protocol	   for	   isolation	   of	  midbody	   from	  HeLa	   cells	   (B)	  MB	   lysate	  from	   HeLa	   cells	   was	   loaded	   along	   with	  total	   cell	   extracts	   from	   interphase	   and	  telophase	  enriched	  cells	  respectively.	  (C)	  IF	  from	  the	  same	  midbody	  fraction	  used	  for	   the	  WB.	   CDKL5	   	   (green)	   and	   alpha-­‐tubulin	  (red).	  TCE:	  Total	  cell	  extract;	   Inter-­‐Interphase;	  Telo-­‐Telophase;	  MB-­‐Midbody	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Figure 12. GFP-CDKL5 truncation derivatives. (A) GFP-wt-CDKL5 (B) GFP-CDKL5-N 
terminal (C) GFP-CDKL5 C-terminal. 
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Figure	  11.	  Expression	  of	  exogenous	  CDKL5	  at	  the	  MB	  of	  HeLa	  cells.	  (A)	  GFP-­‐CDKL5	  was	  transiently	   overexpressed	   in	   HeLa	   cells.	   Exogenously	   expressed	   CDKL5	   (green)	   can	   be	  observed	  in	  the	  MB	  along	  with	  α-­‐tubulin	  (red)	  staining	  the	  MB	  filaments.	  Nuclei	  are	  stained	  with	   DAPI	   (blue).	   (B)	   MB	   fractions	   from	   HeLa	   cells	   transfected	   with	   GFP	   and	   GFP-­‐CDKL5	  expressing	  plasmids	  along	  with	  TCE	   from	   interphase	   cells	   of	   each	   transfected	   sample	  were	  loaded	  for	  biochemical	  analysis.	  I	  -­‐	  Interphase;	  TCE	  -­‐	  Total	  cell	  extract;	  MB	  -­‐	  Midbody	  	  
A 
B 
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Figure 13. The N-terminal portion of CDKL5 is responsible for the midbody localization. 
Total cell extracts of interphase cells and midbody fractions obtained from HeLa cells 
transfected with GFP, GFP-CDKL5, GFP-CDKL5-C term and GFP-CDKL5-N term were 
analyzed by western blot. 
Enrichment of midbody fraction was determined by staining with α-tubulin and phospho-
aurora antibodies. Nuclear and cytoplasmic contaminations were verified by AKT and 
GAPDH respectively. 
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Figure 14: Efficient mitotic spindle formation requires CDKL5. (A) HeLa cells were 
silenced with si-CDKL5 and a si-scramble as a control and stained with α-tubulin (red) to 
monitor the microtubule organization. DNA was stained with DAPI (blue). The image 
shows defects in mitotic spindle organization. (B) CDKL5 silenced HeLa cells show 1.8 
fold increase in the number of mitotic cells. (C) CDKL5 silenced HeLa cells show 2.85 fold 
increase in the number of multipolar cells. (D) CDKL5 silenced HeLa cells show 3.93 fold 
increase in the number of binucleate cells. Values are mean ± s.e.m. n=3, p<0.05   	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Figure 15: CDKL5 depletion causes micronuclei formation: (A) HeLa cells silenced by si-
CDKL5 were stained with DAPI. Micronuclei are indicated with arrows. (B) Quantitative 
analysis of micronuclei count was done from control and CDKL5-silenced HeLa cells using 
ImageJ software. Values are means  ±s.e.m. n =3, p<0.05 
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Figure 16: CDKL5 deficiency reduces migration efficiency in HeLa cells. (A) Migration of 
control and CDKL5 silenced HeLa cells into a scratch wound was monitored by following a time-
course immunofluorescence.  Cells were fixed and stained with DAPI immediately after the 
scratch and 24 hrs later to evaluate the migration ability of HeLa into the wound. (B) A 
quantitative analysis of the migration assay was done using the ImageJ software. n=3, p<0.005 
(C) HeLa cells transfected with scramble and CDKL5 si-RNA were silenced for three days and 
endogenous CDKL5 level was analyzed by western blot. 
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Figure 17. CDKL5 interacts with the scaffold protein IQGAP1 and the abscission proteins 
Tsg101 and Cep55 at the MB. CDKL5 was immunoprecipitated from MB fraction of HeLa cells 
using anti-CDKL5 Ab. CDKL5 interaction with IQGAP1, Tsg101, Cep55 and Ect2 was then   
studied by immunoblotting. Immunoblotting of western blot was done with each Ab as labelled.     
IP-Immunoprecipitation;   (-) – without Ab; (+) – with Ab. 
	   46	  
 
 
 
 
Discussion 
 
Rett syndrome is a progressive neurodevelopmental disorder affecting almost 
exclusively females. The classical form of Rett syndrome is characterized by the 
appearance of neurodevelopment arrest and regression after several months of 
apparently normal development, (Hagberg, 1983). Symptoms that appear during 
this period of infantile life will persist throughout the whole adulthood, 
preventing affected individuals from leading a normal and independent physical 
and social life. 
 
The classical form of RS is often associated with mutations in the MECP2 gene. 
Besides the classical form, also atypical cases of RS have been reported; these 
can be characterized both by milder phenotypes, as is the case for the “preserved 
speech variant”, and by more severe symptoms, as it occurs in the Hanefeld 
variant. Children affected by the Hanefeld variant develop seizures soon after 
birth and the epileptic crisis often become pharmacologically intractable 
(Hanefeld, 1985). Patients affected by the Hanefeld variant often carry mutation 
in the cyclin-dependent kinase-like 5 (CDKL5) gene. CDKL5 mutations have 
also been found in patients affected by the West syndrome, intellectual disability 
and infantile spasms; generally, the common features of all these patients are the 
occurrence of early onset seizures and a delayed neurodevelopment. 
 
CDKL5 is a serine/threonine kinase characterized by a catalytic domain at the N-
terminus, which shares a high homology with that of MAPK and CDK family 
members, and a long C-terminal tail certainly involved in regulating the kinase 
activity, turnover and subcellular localization. In fact, the C-terminal tail is 
known to negatively regulate the catalytic activity of the kinase and is also 
responsible for its localization in the cytoplasm. The presence of putative NLS 
(Nuclear Localization Signal) and NES (Nuclear Export Signal) motifs in the 
COOH domain of CDKL5 influences, in fact, its nucleo-cytolasmic localization 
(Rusconi et al., 2008). The relevance of the COOH terminal in controlling 
CDKL5 localization is strengthened by the pathogenic truncation mutations 
R781X and L879X that appear sequestered in the nucleus (Bertani et al., 2008). 
Eventually, the COOH terminal domain affects the stability of CDKL5. In fact, 
the CDKL5107 isoform is found to be less susceptible to the proteasomal 
degradation as compared to the long CDKL5115 isoform, thus indicating that the 
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very C-terminal region, from amino acid 905, contains signals responsible for 
this degradation (Williamson et al., 2012). 
 
 So far, the majority of the research studies on CDKL5 functions have been 
focused to neurodevelopment. However, a recent work assayed whether the 
kinase affects cell proliferation/differentiation. In particular, this study has shown 
that CDKL5 expression induces differentiation and inhibits the proliferation of 
the SH-SY5Y neuroblastoma cells under the negative regulation of the 
transcription factor MYCN (Valli et al., 2012). 
 
Our work starts from the observation that MeCP2 localizes at the spindle poles 
during early mitotic stages (Bergo et al., submitted for publication) in HeLa cells. 
Since it is known that MeCP2 and CDKL5 belong to the same molecular 
pathway (Mari et al., 2005) we decided to investigate the localization of CDKL5 
in mitotic cells. Our observation that CDKL5 localizes at the spindle poles 
during early mitotic phase, followed by its localization at the midzone and then 
midbody during telophase, suggests a role of the kinase at this transient 
organelle. We also found that both, MeCP2 and CDKL5, localize at the 
centrosome in post-mitotic (DIV4) neurons. This observation is quite remarkable 
with respect to CDKL5 because we were unable to find it in the interphase 
centrosome of dividing cells; it seems that this localization is specific of post 
mitotic neurons, or possibly, and more general, of postmitotic cells. This 
phenomenon might suggest that CDKL5 plays different roles in the interphase of 
diverse cells. Though CDKL5 localization in the centrosome of post-mitotic 
neurons is open to a wide range of possible functions, its role in neuronal 
migration is more plausible. In fact, our data clearly demonstrate that cycling 
cells devoid of CDKL5 are defective in wound healing, and Chen et al. (2010) 
have demonstrated that CDKL5 deficiency in rat brain causes a delay in neuronal 
migration. In the future it will be quite interesting to explore whether CDKL5 
affects neuronal migration through its centrosomal localization. 
 
Having demonstrated that CDKL5 localizes at the midbody, we decided to 
analyze which domain is responsible for this localization. Using a biochemical 
assay we showed that a CDKL5 construct devoid of the catalytic domain doesn’t 
localize at the midbody. Hence, we conclude that the catalytic domain, i.e., the 
N-terminal domain of CDKL5 is responsible for the midbody localization. But 
we were unable to conclude whether the catalytic activity of the kinase is 
required for this localization: its role remains to be ascertained. Furthermore, in 
the future it will be important to address whether CDKL5 affects the 
phosphorylation state of proteins that localize either at the centrosome or the 
midbody. To this regards we want to make the point that so far all certain 
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missense pathogenic mutations fall into the catalytic domain and appears to 
affect the enzymatic activity of CDKL5. 
 
Focusing on dividing cells, we found that CDKL5 deficiency impairs basic 
cellular processes such as spindle pole formation, mitosis and cell migration. 
Defects in normal spindle formation in the absence of CDKL5 are 
understandable considering its presence at the centrosome during early mitotic 
phase. During this study we also observed that CDKL5 deficiency causes an 
increase of mitotic cells. A possible explanation of this phenotype could be that a 
higher number of cells are stuck in mitosis due to the spindle checkpoint 
activation occurring during aberrant mitosis (Wells & Murray 1996). We would 
like to further investigate the role of CDKL5 silencing on the activation of 
spindle checkpoint by analyzing by western blot and immunofluorescence 
proteins that are known for their role in spindle checkpoint activation, such as 
viz., Bub1, BubR1, Mps1 and MAD proteins (Burke 2000). 
 
Eventually, since micronuclei represent a mechanism by which errors in 
chromosome segregation and DNA breaks are eliminated from the nucleus of the 
cell and spindle aberrations can cause chromosome instability, we investigated 
whether CDKL5 deficiency causes an increase in the number of micronuclei 
(Fukasawa 2007). In accordance with our hypothesis, we observed an 
approximately two-fold increase in the number of micronuclei in CDKL5 
silenced HeLa cells as compared to the control, which is obvious due to the 
defective spindle formation. In addition, an increase in binucleate cells after 
CDKL5 silencing suggests a defect in abscission. The observed phenotype 
appears well justified by CDKL5 localization at the midbody during late mitosis; 
in fact, it is very well known that the midbody localizes at the site of abscission, 
where it affects cytokinesis. 
 
Considering that CDKL5 deficiency causes micronuclei formation and 
binucleated cells, we suggest a role of CDKL5 in genetic stability and cancer 
risk. Importantly, a possible association of CDKL5 and leukemia has already 
been suggested (Kawahara et al., 2007) Zang ZJ, Ong CK, Cutcutache I, Yu W, 
Zhang SL, Huang D, Ler LD, Dykema K, Gan A, Tao J, Lim S, Liu Y, Futreal 
PA, Grabsch H, Furge KA, Goh LK, Rozen S, Teh BT, Tan P., 2011). 
Eventually, as mentioned, through a wound-healing assay, we have reported a 
functional role of CDKL5 in cell migration. 
 
Having demonstrated that CDKL5 localizes at the midbody and that CDKL5 
depletion causes several defects in cycling cells that can be linked to the 
midbody, we decided to focus our future research on the mechanisms bringing 
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the kinase to the organelle and the consequence, at the biochemical levels, of 
CDKL5 deficiency. Because of that we interrogated a previously performed two 
hybrid screening, to address whether CDKL5 might have been found interacting 
with protein normally localized in this organelle. In this way we found that 
IQGAP1 (IQ motif containing GTPase activating protein) was proposed as a 
possible interactor of the C-terminal tail of CDKL5. In accordance with the 
genetic screening, by coimmunoprecipitation we found that CDKL5 interacts 
with IQGAP1. IQGAP1 is a multifunctional scaffolding protein that has ability 
to interact with a wide variety of proteins that result in a wide array of functions. 
It is known to affect cell proliferation and migration in NIH3T3 cell line (Wang 
et al., 2009). In neurons it facilitates neuronal migration (Kholmanskikh et al., 
2006), dendrite formation (Swiech et al., 2011), spine development (Gao et al., 
2011), synaptic plasticity (Gao et al., 2011), memory formation (Schrick et al., 
2007) and neurite outgrowth as well as polarization as reviewed by Jausoro et al., 
(Jausoro et al., 2012). A review has highlighted that IQGAP1 is overexpressed in 
many human malignancies at both mRNA and protein level (White et al., 2009), 
and a direct evidence of IQGAP1 involvement in cancer progression has been 
proved both in vitro and in vivo by Jadeski et al. (Jadeski et al., 2008). 
Importantly, since the C-terminal domain seems to be involved in the identified 
interaction, whereas CDKL5 N-terminal domain appears to be required for its 
localization at the midbody, we suggest that CDKL5 might be important for 
IQGAP localization at the midbody and/or might regulate its activity/localization 
through phosphorylation. In the future work, mainly through 
immunofluorescence assays coupled to specific shRNAs we will test these 
possibilities.  
 
Eventually, we have started to address whether other proteins of the midbody 
interact with CDKL5. Although we are aware that a much more exhaustive 
analysis is required, for the time being we have found that CDKL5 interacts with 
two proteins Cep55 and Tsg101. Cep55 is a coiled-coil protein that is required 
for the establishment and proper function of the midbody structure. In Cep55 
knockdown cells there is an abrogation of midbody formation, and the structural 
and regulatory components of the midbody are either absent or mislocalized. In 
addition, it facilitates membrane fusion during the terminal stage of cytokinesis 
that results in abscission (Zhao et al., 2006). The other interactor of CDKL5 in 
the midbody, Tsg101, is a subunit of human ESCRT-1 complex, a regulator of 
vesicle trafficking process. It helps in the formation of multivesicular bodies 
(MVBs) and also retroviral budding which is an event similar to the cytokinesis 
of eukaryotic cells (Carlton & Martin-Serrano 2007).  It is interesting to note that 
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Tsg101 interacts with Cep55 and IQGAP1 along with other proteins to facilitate 
cytokinesis (Morita et al., 2007). 
 
On the contrary we didn’t observe any interaction of CDKL5 with another 
abscission protein Ect2. Ect2 is a guanine nucleotide exchange factor and 
transforming protein that is related to Rho-specific exchange factors and yeast 
cell cycle regulators. The expression of this gene is elevated with the onset of 
DNA synthesis and remains elevated during G2 and M phases.  This protein 
plays an important role in the regulation of cytokinesis (Tatsumoto et al., 1999), 
epithelial cell polarity (Liu et al., 2004), tumor cell proliferation (Justilien & 
Fields 2009) and it controls the formation of mitotic spindle assembly 
(Tatsumoto et al., 2003). 
 
Taking cues from our observations we would like to address the following 
questions in the near future: 
 a. Determine the domain of CDKL5 that interacts with Cep55 and Tsg101 
     at the midbody. 
 b. Determine if CDKL5 is involved in the correct localization of IQGAP1, 
     Cep55 and Tsg101 at the midbody. 
 c. Does CDKL5 phosphorylate IQGAP1, Cepp55 and Tsg101 at the         
     midbody? 
 d. Since CDKL5 localizes at the centrosome during prophase and its    
     absence causes defective spindle formation we would like to know     
     whether CKL5 depletion cause impairment of microtubule nucleation? 
e. Determine if there is a role of centrosome in delayed migration in  
CDKL5 depleted HeLa cells. 
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